Tag: glucagon-like peptide-1 (GLP-1) receptor agonists

1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%. 2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated. Evidence Rating Level: 1 (Excellent) Study Rundown: In many patients...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like...
1. Over a median period of almost 16 months, type 2 diabetic (T2DM) patients randomized to oral semaglutide for experienced a similar rate of cardiovascular (CV) events compared to placebo treated patients. 2. Discontinuation of therapy due to gastrointestinal issues occurred more often in the semaglutide group. Evidence Rating Level: 1...